Fullerene-based Radioprotectors for Use during Brain Radiotherapy, Period of Performance 09/15/2014 - 05/15/2015

用于脑部放射治疗期间使用的富勒烯放射防护剂，执行期间 09/15/2014 - 05/15/2015

• 批准号: 8948732
• 负责人: Zhiguo Zhou
• 金额: $ 20万
• 依托单位: LUNA INNOVATIONS, INC.
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-09-19 至 2015-06-18
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8948732
• 关键词: Aging; Anti-Inflammatory Agents; Antioxidants; Brain; Brain Injuries; Brain Neoplasms; Clinical Trials; Cranial Irradiation; Effectiveness; Fullerenes; Goals; Impaired cognition; In Vitro; Inflammation; Measurement; Metastatic malignant neoplasm to brain; Modality; Neurodegenerative Disorders; Normal Cell; Patients; Performance; Phase; Primary Brain Neoplasms; Quality of life; Radiation; Radiation Tolerance; Radiation therapy; Risk; Safety; Small Business Innovation Research Grant; Survivors; Therapeutic; Tissues; base; brain cell; brain tissue; cancer cell; cognitive function; improved; in vivo; mimetics; neoplastic cell; preclinical study; programs; protective effect; research study; therapy outcome

It is estimated that there are 22,910 new cases of primary brain tumor and 500,000 new cases of brain metastases each year. A majority of these patients will receive fractionated whole or partial brain irradiation as part of their treatment, putting them at risk for developing late radiation-induced brain injury, including a progressive decline in cognitive function. Radiation is also the primary treatment modality for brain metastases. The diminished quality of life of most survivors has become an important and growing concern, being recognized as one of the most important measurements of brain tumor therapy outcomes, second only to survival in clinical trials. Currently, there are no proven successful long-term treatments or effective preventative strategies for radiation-induced cognitive impairment. Luna proposes to develop a fullerene-based radioprotector for use during brain radiotherapy to improve the quality of life of those survivors. Fullerene has been shown effective to delay aging and treat neurodegenerative diseases as a catalytic antioxidant, SOD-mimetic and anti-inflammatory agent. The proof-of concept will be demonstrated through in vitro and in vivo experiments in Phase I and Phase II will focus on advanced preclinical studies to demonstrate safety and effectiveness to improve the therapeutic ratio of radiation.

据估计，每年有22，910例原发性脑肿瘤新发病例和50万例脑转移新发病例。这些患者中的大多数将接受分次全脑或部分脑照射作为治疗的一部分，使他们有发生晚期放射性脑损伤的风险，包括认知功能的进行性下降。放射也是脑转移瘤的主要治疗方式。大多数幸存者的生活质量下降已成为一个重要且日益增长的问题，被认为是脑肿瘤治疗结果的最重要指标之一，仅次于临床试验中的生存率。目前，对于辐射引起的认知障碍，还没有被证明是成功的长期治疗或有效的预防策略。Luna建议开发一种基于富勒烯的辐射防护剂，用于脑放射治疗，以改善幸存者的生活质量。富勒烯作为一种催化抗氧化剂、SOD模拟剂和抗炎剂，已被证明能有效延缓衰老和治疗神经退行性疾病。概念验证将通过I期和II期的体外和体内实验进行证明，II期将侧重于先进的临床前研究，以证明提高放射治疗率的安全性和有效性。